Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAD study of KSHN001126 in healthy postmenopausal women
NCT06467201Phase 1Completed
- Sponsor
- Amneal Pharmaceuticals, Inc.
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules, Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label trial of KSHN001126 in breast cancer, sponsored by Amneal Pharmaceuticals, Inc. Primary endpoints: Adverse Events at 15 days, Number of participants with abnormal laboratory tests results at 15 days and 2 more. Started Jun 2024; status: completed.
02
Drugs
KSHN001126
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06467201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467201.